Adipose-Derived Therapies for Hair Loss
Adipose tissue, or body fat, contains a complex mixture of cells and biological signaling molecules that has become an important area of regenerative medicine research. In hair loss, adipose-derived approaches have been studied primarily for androgenetic alopecia, with smaller amounts of research involving alopecia areata and other forms of nonscarring hair loss.
The term “adipose-derived stem cell therapy” can be misleading because the treatments studied in humans are not all the same. Some involve cellular material isolated from a patient’s own fat. Others involve stromal vascular fraction, or SVF, which contains many different cell types. Still others use conditioned media, secretome, extracellular vesicles or cell-derived extracts that contain no living stem cells at all.
These distinctions matter. A positive study involving one adipose-derived preparation does not establish that every treatment marketed as “stem cell therapy” will produce the same result. Current human studies provide legitimate evidence that some adipose-derived preparations may improve hair density, hair diameter or other measures of follicular activity in selected patients, but the field remains investigational, protocols vary substantially and no adipose-derived stem-cell or SVF treatment is FDA approved for hair loss.
What Are Adipose-Derived Therapies?
Adipose tissue is much more than stored fat. It also contains blood vessels, connective tissue, immune cells, endothelial cells, pericytes, precursor cells and populations commonly described in the literature as adipose-derived stromal/stem cells, or ADSCs.
Researchers became interested in these cells because adipose tissue is relatively accessible and because adipose-derived stromal cells release numerous growth factors, cytokines and signaling molecules that may influence tissue repair, blood vessel formation and cellular activity.
In hair research, several very different adipose-derived approaches have been investigated:
- Stromal vascular fraction, or SVF, a heterogeneous mixture of cells isolated from adipose tissue
- Adipose-derived stromal/stem cells, which may be isolated and sometimes expanded or otherwise processed
- ADSC conditioned medium, the nutrient medium collected after cultured cells have released growth factors and other signaling molecules into it
- ADSC secretome, a broader term describing proteins, cytokines, growth factors and extracellular vesicles released by cultured cells
- Cell-derived extracts or constituent extracts, which contain biological components derived from adipose-derived cells but no living stem cells
These approaches are not interchangeable.
What Is Stromal Vascular Fraction?
Stromal vascular fraction is obtained from adipose tissue after much of the mature fat-cell component has been removed. SVF is not a purified population of stem cells. It contains a mixture of mesenchymal stromal cells, endothelial cells, pericytes, immune cells, vascular progenitor cells and other cellular components.
This is important because clinics sometimes use the terms “SVF,” “ADSC” and “stem cell treatment” as though they describe the same thing. They do not.
The number and composition of cells in an SVF preparation can vary according to the tissue source, harvesting method, enzymatic or mechanical processing, centrifugation method and other procedural factors. That variability makes comparisons among clinical studies difficult.
What Are Adipose-Derived Stromal/Stem Cells?
Adipose-derived stromal/stem cells are mesenchymal stromal cell populations obtained from fat tissue. The literature frequently refers to them as “stem cells” because selected cell populations can demonstrate multipotent behavior under laboratory conditions.
That term can give consumers the inaccurate impression that these cells are injected into the scalp and then transform directly into new hair follicles.
That has not been demonstrated in human hair-loss treatment.
The more plausible biological rationale involves the signaling molecules these cells produce and their potential influence on existing follicular cells, vascular structures and the surrounding tissue environment.
What Is Conditioned Medium?
Adipose-derived stem cell conditioned medium, commonly abbreviated ADSC-CM, is fundamentally different from a cellular stem-cell treatment.
ADSCs are grown under controlled conditions. During culture, the cells release growth factors, cytokines and other biological molecules into the surrounding medium. The cells themselves are then removed, leaving behind a cell-free solution containing their secreted products.
Human studies using conditioned media therefore should not be described as evidence that injected stem cells regrow hair. No living adipose-derived stem cells are being administered in these preparations.
This distinction is particularly important because a meaningful portion of the clinical literature in this area involves conditioned media or other cell-derived products rather than transplantation of living stem cells.
What Is the Secretome?
The secretome refers collectively to substances released by cells. This can include growth factors, cytokines, chemokines, proteins, lipids and extracellular vesicles.
Exosomes are one type of extracellular vesicle and are discussed separately in the AHLA’s Exosomes section. A secretome preparation may therefore overlap biologically with exosome research but should not automatically be described as an exosome product.
Different manufacturing and culture methods can produce preparations containing very different concentrations and combinations of biological molecules.
How Might Adipose-Derived Therapies Affect Hair Follicles?
The precise mechanisms remain under investigation. Laboratory studies suggest that adipose-derived stromal cells and their secreted products can influence signaling pathways involved in follicular growth, vascular development and the transition of follicles into the active anagen phase.
Proposed mediators include vascular endothelial growth factor, hepatocyte growth factor, insulin-like growth factor and other signaling molecules. Researchers have also investigated effects on dermal papilla cells, which play an important role in regulating the hair cycle.
These mechanisms provide a reasonable biological rationale for clinical research. They do not prove that an adipose-derived treatment will reverse androgenetic alopecia in an individual patient.
Can Adipose-Derived Stem Cells Create New Hair Follicles?
There is currently no established clinical evidence that adipose-derived treatment can create an entirely new population of fully functional human scalp hair follicles.
This is one of the most important distinctions for consumers. A miniaturized follicle affected by androgenetic alopecia is still an existing follicle. Improving the activity or diameter of hair emerging from that follicle is very different from generating a completely new follicular organ.
Claims that adipose-derived stem-cell treatment can “create new follicles,” “replace dead follicles” or reliably regenerate areas where follicles have already been destroyed go beyond current clinical evidence. Existing research is better understood as an attempt to improve the function of follicles that remain biologically viable.
What Is the Evidence for Androgenetic Alopecia?
Androgenetic alopecia has been the primary focus of clinical research. Several controlled trials, prospective studies and systematic reviews have reported increases in hair density, diameter or related measures after treatment with adipose-derived preparations.
The overall evidence is encouraging enough to justify continued research, but the clinical literature remains highly heterogeneous. Studies have used different cell preparations, different concentrations, different injection techniques, topical application, fractional laser-assisted delivery, different treatment schedules and different combinations with PRP, minoxidil or other therapies.
That makes it difficult to determine which particular adipose-derived treatment, if any, should become a standardized clinical therapy.
The 2020 Randomized ADSC Extract Trial
One of the more important controlled studies evaluated a cell-free adipose-derived stem cell constituent extract, rather than injected living stem cells.
Thirty-eight patients with androgenetic alopecia, including 29 men, were randomized to a topical ADSC-derived constituent extract or vehicle. Thirty-four completed the 16-week study, with the solution applied twice daily.
At week 16, mean hair count had increased approximately 28.1 percent from baseline in the treatment group compared with approximately 7.1 percent in the vehicle group. Hair diameter increased approximately 14.2 percent in the treatment group compared with 6.3 percent in controls.
Those objective phototrichogram findings are meaningful. However, blinded investigator global photographic assessments did not show a statistically significant between-group difference, and patient self-assessments also did not significantly favor treatment.
This distinction is important. Statistically measurable changes in hair count and diameter do not always translate into clearly visible cosmetic improvement.
The study also does not demonstrate that injecting a patient’s own adipose-derived cells into the scalp would produce the same result. The intervention was a specific topical cell-derived extract.
What Does the Research on Conditioned Medium Show?
Conditioned medium has one of the larger clinical evidence bases within adipose-derived hair research.
An early study treated 22 men and women with alopecia using intradermal injections of adipose-derived stem cell conditioned medium every three to five weeks for six sessions. Hair counts increased after treatment, and a smaller half-scalp comparison involving 10 patients showed greater improvement on the treated side.
The authors also observed some improvement on the control side and acknowledged that local injection effects or diffusion could have contributed. This makes the study encouraging but not definitive.
A separate retrospective study involving 27 women with female pattern hair loss reported increases in hair density and diameter after ADSC conditioned-medium treatment. Other studies have investigated conditioned medium following fractional laser treatment or in combination with established therapies.
A broader 2024 systematic review and meta-analysis evaluated stem-cell-derived conditioned media from several cellular sources, not adipose-derived products alone. Across eight trials involving 221 patients included in the quantitative analysis, pooled results showed improvements in hair density and thickness.
Those findings support continued investigation of conditioned media as a regenerative strategy, but they should not be interpreted as an efficacy estimate for ADSC-CM specifically.
Does Adding Conditioned Medium to Minoxidil Work Better?
Not necessarily.
A randomized double-blind study in men with androgenetic alopecia compared adipose-derived stem-cell conditioned medium with placebo while patients used topical 5 percent minoxidil.
Hair count, density and thickness improved during the short study, but there was no statistically significant difference between the conditioned-medium and placebo-treated sides.
This is an important counterbalance to more favorable uncontrolled studies.
When an established treatment such as minoxidil is being used at the same time, improvement cannot automatically be attributed to the regenerative product. Combination studies should be interpreted according to whether the experimental component actually outperformed the active background treatment or placebo.
What Does the Evidence Show for Stromal Vascular Fraction?
Clinical studies of SVF have also reported encouraging results.
A systematic review of autologous adipose-derived SVF for nonscarring alopecia identified six studies involving 188 patients, including three randomized controlled trials. The studies generally reported improvements in hair density, and some also reported increases in hair diameter or improvements in hair-pull testing.
No severe adverse events were reported in those relatively small studies.
A later systematic review focused specifically on SVF in androgenetic alopecia and again found generally favorable changes in hair density and diameter while emphasizing the absence of a standardized treatment protocol.
The number of cells delivered, preparation method, treatment frequency and use of additional therapies differed substantially between studies. Promising early results therefore do not establish one reproducible SVF treatment protocol.
Does SVF Work Better Than PRP?
The evidence does not establish that it does.
Some earlier research combining SVF with PRP reported favorable results, which contributed to the perception that adding a cellular component might produce a stronger regenerative effect.
A randomized clinical trial published in 2024 produced a more cautious result. Eighteen patients were randomized to receive either three PRP sessions or one SVF session followed by two PRP sessions.
Both groups improved in hair count and hair diameter. The PRP-only group had a numerically greater increase in mean hair count, while the SVF-containing group had a slightly greater increase in hair diameter. Neither between-group difference was statistically significant.
In other words, one SVF treatment followed by two PRP treatments did not outperform three PRP treatments on the measured outcomes.
That is an important finding for consumers being told that a more complicated and expensive cell-based treatment must necessarily be superior to PRP.
More sophisticated treatment does not automatically mean better treatment.
What Do the Newer Evidence Reviews Show?
The clinical literature has continued to expand.
A 2024 systematic review of randomized trials involving cellular and acellular stem-cell-derived treatments for androgenetic alopecia reported encouraging findings across several regenerative approaches. However, the included interventions came from several different tissue sources, not adipose tissue alone, and should not be interpreted as evidence for a single ADSC treatment.
A broader 2026 systematic review examined conditioned media, platelet-rich fibrin, SVF, extracellular vesicles and stem-cell-based therapies in androgenetic alopecia. Twenty clinical studies involving 724 patients were included, with conditioned media representing the largest portion of the evidence base.
The review reported favorable changes in hair density and other endpoints across several regenerative approaches, but products, study designs, treatment methods and follow-up periods varied substantially.
This growing research base makes it inappropriate to dismiss adipose-derived therapy as purely theoretical. It also makes it inappropriate to describe the field as settled.
The central unanswered question is no longer simply whether biological activity exists. It is which preparation, produced how, administered how often, to which patients, provides a clinically meaningful and durable benefit that justifies the cost and procedural risk.
What About Female Pattern Hair Loss?
Women have been included in several adipose-derived treatment studies. Conditioned-medium case series and some controlled trials have reported improvements in density and hair diameter in women with female pattern hair loss.
However, female hair loss is biologically and diagnostically complex. Diffuse thinning in women can reflect androgenetic alopecia, telogen effluvium, inflammatory disease, endocrine abnormalities, nutritional problems or combinations of these conditions.
A regenerative treatment should not be offered simply because a woman reports diffuse thinning. The diagnosis needs to be established first.
There is also no evidence that adipose-derived therapy removes the underlying genetic susceptibility responsible for female pattern hair loss.
What About Alopecia Areata?
The evidence is much more limited.
A 2018 study treated 20 patients with alopecia areata using autologous adipose-derived stromal vascular cells obtained after fat harvesting and processing.
The authors reported an increase in mean hair density from approximately 85 hairs per square centimeter at baseline to approximately 121 hairs per square centimeter at six months. Mean hair diameter increased from approximately 60.5 to 80.8 micrometers.
Those are striking changes.
However, the study was small, had no randomized placebo control and was retrospectively registered. Results of that magnitude from an uncontrolled study should generate further research, not establish clinical efficacy.
Alopecia areata is an autoimmune disease. Current evidence for corticosteroids and, in severe disease, FDA approved JAK inhibitors is substantially stronger.
Adipose-derived cellular therapy should therefore remain investigational for alopecia areata and should not delay established disease-specific treatment.
Does It Treat Scarring Alopecia?
There is no established role for adipose-derived therapy in restoring follicles that have already been destroyed by scarring alopecia.
Once a follicular structure has been permanently replaced by fibrosis, current regenerative injections have not been shown to recreate a fully functional follicle.
Research into wound healing, tissue remodeling and regenerative signaling may eventually have relevance to scarring disorders, but that is different from established clinical treatment.
Patients with lichen planopilaris, frontal fibrosing alopecia, central centrifugal cicatricial alopecia or another scarring process need treatment directed at controlling the underlying disease before additional permanent follicles are lost.
How Are Cellular Treatments Performed?
Procedures involving autologous adipose-derived cells generally begin by obtaining fat from the patient’s body through a small-volume liposuction or lipoaspiration procedure.
The tissue is then processed to isolate or concentrate the desired cellular fraction. Depending on the method, processing may involve washing, centrifugation, mechanical disruption, filtration, enzymatic digestion or combinations of these techniques.
The resulting cellular preparation is then injected into the scalp.
That is substantially different from PRP, which is obtained through a blood draw. It is also different from conditioned medium or other cell-free products, which can be manufactured from cultured cell populations and do not require the patient to undergo fat harvesting.
Consumers should know exactly which procedure and product are actually being proposed.
Is a Patient Always Receiving His or Her Own Cells?
No.
Some SVF procedures use autologous material obtained from the same patient.
Conditioned media, secretome, extracts and extracellular-vesicle preparations may instead be produced from donor-derived cell cultures. Those products contain different biological material and can have completely different manufacturing and regulatory considerations.
The phrase “adipose stem cell treatment” does not tell a patient enough to know what is actually being administered.
Is Adipose-Derived Therapy FDA Approved for Hair Loss?
No.
There is no FDA approved adipose-derived stem-cell or SVF treatment for androgenetic alopecia, alopecia areata or any other form of hair loss.
Using a patient’s own tissue does not automatically place a procedure outside FDA regulation.
FDA considers adipose tissue a structural tissue whose relevant basic functions include cushioning and support. When adipose tissue is enzymatically processed to remove mature adipocytes and structural components in order to isolate SVF, FDA has treated that processing as more than minimal manipulation because it alters the original characteristics of the tissue related to those structural functions.
Using isolated adipose-derived cells to treat hair loss also does not perform the same basic structural function that adipose tissue performs in the donor. FDA enforcement actions have therefore treated many disease-directed SVF uses as non-homologous.
Depending on the specific product, manufacturing process and intended use, an adipose-derived cellular product may be regulated as a drug and biological product requiring appropriate FDA authorization or approval.
Regulatory classification remains product specific, but patients should be skeptical of blanket claims that a treatment is exempt from FDA oversight simply because the cells came from their own body.
What Does “Autologous” Mean?
Autologous means the tissue or cells come from the same person who receives them.
Using autologous material can reduce some immunologic and donor-transmission risks, but it does not prove effectiveness and does not eliminate risks from tissue harvesting, processing, contamination, injection or inappropriate cellular manipulation.
The statement “these are your own cells” should never be used as a substitute for clinical evidence.
What Are the Potential Risks?
Short-term clinical hair studies have generally reported few serious complications, but those studies have been relatively small and have often followed patients for only several months.
Cellular SVF treatment can involve risks from the fat-harvesting procedure itself, including pain, bruising, bleeding, infection, scarring, anesthesia-related complications and contour irregularities.
Processing and scalp injection introduce additional concerns involving sterility, contamination, inflammation, pain, swelling and infection.
Cell-free products introduce different questions. Their safety depends on the source cells, culture conditions, manufacturing process, purification, storage, sterility and quality control.
FDA has reported serious complications with unapproved regenerative medicine products used in other areas of medicine, including infections and abnormal tissue growth. Those broader warnings should not be interpreted as evidence that these complications have been demonstrated specifically in scalp adipose-derived hair studies, but they illustrate why manufacturing and regulatory oversight matter.
Long-term safety data for repeated regenerative scalp treatment remain limited.
Is There a Risk of Tumor Formation?
No tumor signal has emerged from the small hair-loss studies published to date.
However, those studies are too small and too short to exclude rare or long-latency complications. FDA has reported abnormal tissue growth and tumor formation with unapproved regenerative medicine products used in other medical contexts.
That broader experience does not establish a tumor risk from properly conducted adipose-derived scalp treatment, but it means claims of “zero cancer risk” go beyond the evidence.
Patients with active malignancy, recent cancer treatment or unusual scalp lesions should discuss any proposed regenerative procedure with the physicians managing those conditions.
What About Infection and Product Sterility?
Sterility is particularly important for any material injected into the scalp.
A cell or biological preparation can become contaminated during tissue harvesting, processing, culturing, storage or administration. Complexity increases the number of opportunities for manufacturing or sterility failures.
A patient considering a cellular or cell-derived product should understand where it was produced, whether processing occurs in the clinic or in an outside laboratory, what sterility and quality-control standards are used and what exactly is contained in the final preparation.
The words “regenerative,” “natural” and “autologous” do not answer those questions.
Is More Stem Cell Material Better?
There is no established dose-response relationship showing that delivering more adipose-derived cells necessarily produces more hair.
Studies have used different cell concentrations, processing methods and treatment schedules. Systematic reviews repeatedly identify lack of standardization as one of the central limitations of the field.
A clinic should therefore be able to explain the evidence supporting the particular cell number, concentration and treatment schedule it recommends.
Higher cell counts or more aggressive processing should not automatically be interpreted as more effective.
How Many Treatments Are Needed?
There is no established treatment schedule.
Some SVF studies have used a single procedure. Others have combined one SVF treatment with subsequent PRP treatments.
Conditioned-medium studies have used repeated injections or topical applications over several weeks or months.
Because these products are fundamentally different, there is no scientifically established universal schedule such as “three stem-cell treatments” or “one treatment every six months.”
A commercial protocol should not be mistaken for a validated clinical standard.
How Long Do Results Last?
Long-term durability remains one of the biggest unanswered questions.
Most studies have followed patients for several months rather than several years.
Androgenetic alopecia is a chronic progressive genetic disorder. Even if an adipose-derived treatment temporarily improves follicular activity, it has not been shown to remove the underlying androgen sensitivity of susceptible follicles.
There is therefore no reason to assume that a short series of regenerative injections permanently stops pattern hair loss.
Patients should be cautious when treatment is marketed as a one-time permanent solution.
Does It Replace Finasteride, Dutasteride, Minoxidil or Other Established Therapy?
No evidence currently supports that conclusion.
Adipose-derived treatments target different biological pathways than finasteride, dutasteride or minoxidil. In a patient with androgenetic alopecia, the presence of a regenerative treatment does not remove the underlying genetic and hormonal drivers of progressive follicular miniaturization.
Some clinical studies have combined regenerative therapies with minoxidil, PRP or other established treatments. When combination treatment is used, improvement should not automatically be credited to the experimental component.
For most patients, regenerative therapy should currently be considered investigational or adjunctive rather than an evidence-based replacement for established medical treatment.
What About Combining It With PRP?
SVF and PRP have frequently been combined.
There is a theoretical rationale because PRP provides platelet-derived signaling molecules while SVF contributes a mixture of cells and additional biological factors.
Some early studies reported greater improvement with SVF plus PRP than with PRP alone.
However, the 2024 randomized comparison found no significant advantage when one SVF treatment followed by two PRP sessions was compared with three PRP sessions alone.
This is precisely why controlled comparisons matter.
Adding another biological product can increase complexity and cost without necessarily increasing clinical benefit.
What About Fractional Laser or Microneedling Delivery?
Fractional laser-assisted delivery has been studied with conditioned media and other topical regenerative preparations. Controlled microscopic channels created by a research laser protocol may alter penetration and can produce a treatment exposure different from simple application to intact scalp.
Home microneedling followed immediately by an unstandardized biological product is a different practice and has a much weaker safety and pharmacokinetic evidence base.
Evidence supporting conditioned medium after a specific fractional-laser protocol should therefore not be extrapolated automatically to home microneedling followed by an unrelated compounded or commercially marketed regenerative product.
Barrier disruption can alter penetration and potentially systemic exposure.
The AHLA does not consider routine home microneedling immediately followed by an unstandardized adipose-derived biological product an established treatment strategy.
What About Pregnancy and Breastfeeding?
There are no adequate clinical studies establishing the safety of adipose-derived cellular or cell-derived hair treatments during pregnancy or breastfeeding.
Hair treatment is elective, and the products and procedures themselves vary substantially.
Pregnant patients should not assume that a treatment is safe because it is derived from human cells or from their own tissue. The same caution applies during breastfeeding, particularly when the biological composition and systemic exposure of the administered product have not been adequately characterized.
What Should Someone Ask Before Considering Adipose-Derived Therapy?
A patient should know exactly what type of treatment is being proposed and should ask:
- Is the treatment cellular or cell-free?
- Does it contain SVF, isolated cells, conditioned medium, secretome, extracellular vesicles or another preparation?
- Is the material autologous or donor derived?
- Where is it processed?
- How is it processed?
- Is the actual preparation being offered the same preparation used in the study being cited?
- Has that specific type of treatment been studied in human hair loss?
- What regulatory framework applies to it?
- What objective outcome will be measured?
- How long will treatment be tried before judging efficacy?
- Will established medical therapy continue?
- What complications are possible?
- How is sterility maintained?
- What long-term follow-up exists?
If the explanation consists primarily of phrases such as “your own stem cells,” “regeneration,” “growth factors” or “activating dormant follicles” without identifying the actual preparation and evidence, the patient does not yet have enough information to make an informed decision.
The AHLA Perspective
Adipose-derived therapies represent a legitimate and rapidly evolving area of hair research.
They should neither be dismissed as pseudoscience nor marketed as though “stem cell hair restoration” is already an established treatment.
There is real human clinical evidence. Controlled studies of cell-free adipose-derived extracts and conditioned media have demonstrated measurable changes in hair density or diameter. SVF studies have also reported encouraging outcomes, and systematic reviews now include a growing number of human trials.
But those findings do not validate every commercial treatment sold under the stem-cell label.
The field contains several fundamentally different interventions. SVF is not purified stem cells. Conditioned medium contains no living stem cells. Secretome is not necessarily the same as an exosome preparation. A topical cell-derived extract is not equivalent to surgically harvesting fat and injecting SVF into the scalp.
That distinction is central.
The AHLA is particularly concerned when consumers are told that adipose-derived cells will transform into new hair follicles or permanently regenerate bald scalp. Current clinical evidence does not establish that.
The more defensible interpretation is that certain adipose-derived preparations may influence the activity of existing viable follicles and may eventually become useful adjunctive treatments for androgenetic alopecia.
The 2024 randomized comparison of SVF plus PRP versus PRP alone also provides an important reminder: a more invasive, expensive or technologically complex procedure does not necessarily produce a better result.
Regulatory status matters as well. There is no FDA approved adipose-derived stem-cell or SVF treatment for hair loss, and obtaining cells from a patient’s own fat does not automatically exempt a product or procedure from FDA regulation.
For now, the appropriate standard is careful diagnosis, transparent identification of exactly what is being administered, objective documentation of results, realistic expectations and continued reliance on established therapy when appropriate.
The science is promising, but clinical claims should not move faster than the evidence.
Selected References
- Tak YJ, Lee SY, Cho AR, Kim YS. A Randomized, Double-Blind, Vehicle-Controlled Clinical Study of Hair Regeneration Using Adipose-Derived Stem Cell Constituent Extract in Androgenetic Alopecia. Stem Cells Transl Med. 2020;9:839-849. doi:10.1002/sctm.19-0410. PubMed
- Fukuoka H, Suga H. Hair Regeneration Treatment Using Adipose-Derived Stem Cell Conditioned Medium: Follow-up With Trichograms. Eplasty. 2015;15:e10. PubMed Central
- Legiawati L, et al. Adipose-Derived Stem Cell Conditioned Medium as an Adjunct to Minoxidil in Androgenetic Alopecia: A Randomized, Double-Blind Study. Stem Cell Res Ther. 2023. Full Text
- Kang BY, Li AW, Lee MH, et al. The Safety and Efficacy of Autologous Adipose-Derived Stromal Vascular Fraction for Nonscarring Alopecia: A Systematic Review. Arch Dermatol Res. 2022;314:349-356. doi:10.1007/s00403-021-02238-7. PubMed
- Behrangi E, Rahimi ST, Zare S, et al. Evaluation of the Effects of Adding an Adipose Tissue-Derived Stromal Vascular Fraction to Platelet-Rich Plasma Injection in the Treatment of Androgenetic Alopecia: A Randomized Clinical Trial. Skin Res Technol. 2024;30:e13700. doi:10.1111/srt.13700. PubMed
- Chien WY, Huang HM, Kang YN, Chen KH, Chen C. Stem Cell-Derived Conditioned Medium for Alopecia: A Systematic Review and Meta-Analysis. J Plast Reconstr Aesthet Surg. 2024;88:182-192. doi:10.1016/j.bjps.2023.10.060. PubMed
- Gasteratos K, Kouzounis K, Goverman J. Autologous Stem Cell-Derived Therapies for Androgenetic Alopecia: A Systematic Review of Randomized Controlled Trials on Efficacy, Safety, and Outcomes. Plast Reconstr Surg Glob Open. 2024;12:e5606. doi:10.1097/GOX.0000000000005606. PubMed
- Behrangi E, Amiri S, Zeinali R, et al. Clinical Evidence for Regenerative Therapies in Androgenetic Alopecia: Conditioned Media, Platelet-Rich Fibrin, Stromal Vascular Fraction, Extracellular Vesicles, and Stem Cells. Stem Cell Res Ther. 2026;17:194. doi:10.1186/s13287-026-05016-2. PubMed
- Anderi R, Makdissy N, Azar A, Rizk F, Hamade A. Cellular Therapy With Human Autologous Adipose-Derived Adult Cells of Stromal Vascular Fraction for Alopecia Areata. Stem Cell Res Ther. 2018;9:141. doi:10.1186/s13287-018-0889-y. PubMed
- U.S. Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies. FDA